Assessment of Imatinib Anti-Remodeling Activity on a Human Precision Cut Lung Slices Model.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 28 06 2024
revised: 19 07 2024
accepted: 25 07 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 10 8 2024
Statut: epublish

Résumé

Recent studies have emphasized the critical role of alteration in cellular plasticity in the development of fibrotic disorders, particularly pulmonary fibrosis, prompting further investigation into molecular mechanisms and therapeutic approaches. In this context, Precision Cut Lung Slices (PCLSs) emerge as a valuable ex vivo research tool. The process of PCLSs generation preserves most features of the naïve lung tissue, such as its architecture and complex cellular composition. We previously stimulated normal lung PCLSs with two different stimuli (fibrotic cocktail, composed by platelet lysate and TGFβ, or neutrophil extracellular traps) and we observed a significant elevation of Epithelial-Mesenchymal Transition (EMT) markers from 24 h to 72 h of culture. The aim of our work was to exploit this PCLSs based ex vivo model of EMT, to evaluate the effect of imatinib, an old tyrosine kinase inhibitor with reported anti-remodeling activities in vitro and in animal models. Imatinib treatment significantly decreased α-SMA and collagen expression already starting from 24 h on stimulated PCLS. Imatinib showed a significant toxicity on unstimulated cells (3-fold increase in

Identifiants

pubmed: 39125756
pii: ijms25158186
doi: 10.3390/ijms25158186
pii:
doi:

Substances chimiques

Imatinib Mesylate 8A1O1M485B
Protein Kinase Inhibitors 0
Actins 0
ACTA2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Foundation IRCCS Policlinico San Matteo
ID : Ricerca corrente grants 982-rcr2021i-13
Organisme : Ministry of Health
ID : Ricerca Finalizzata grant rf-2021-12374476

Auteurs

Sara Bozzini (S)

Second Department of Anesthesia and Cardiothoracic ICU[M1] [BS2], IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Eleonora Bozza (E)

Department of Pediatric Oncoaematology, Cell Factory, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Cecilia Bagnera (C)

Department of Pediatric Oncoaematology, Cell Factory, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Patrizia Morbini (P)

S.C. Anatomia e Istologia Patologica, E.O. Ospedali Galliera, 16128 Genova, Italy.

Sara Lettieri (S)

Respiratory Diseases Unit, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Matteo Della Zoppa (M)

Respiratory Diseases Unit, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Giulio Melloni (G)

Department of Thoracic Surgery, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Laura Saracino (L)

Respiratory Diseases Unit, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Mirko Belliato (M)

Second Department of Anesthesia and Cardiothoracic ICU[M1] [BS2], IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Federica Meloni (F)

Department of Cardio-Thoracic, Vascular Sciences and Public Health, University of Padua, 35122 Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH